11/7/26 Mapping the Rare Patient Journey Previous From Awareness to Activation - Converting Rare Patient Identification into Trial Enrollment Next Patient Input and Digital Health Technologies: A Regulatory Perspective Across the Product Lifecycle You Might Also Like Leveraging Natural History and RWE for Rare Approvals Mock Formal FDA Meeting: How to Respond When FDA Disagrees Platform and Basket Trials in Rare Disease: What’s Working, What Isn’t, and What It Takes to Scale Bridging the Generational Divide in Rare Disease Clinical Trials: Tailoring Communication to Maximize Recruitment, Retention, and Equity Retention by Design - Keeping Families Engaged for Multi-Year Studies
11/7/26 Mapping the Rare Patient Journey Previous From Awareness to Activation - Converting Rare Patient Identification into Trial Enrollment Next Patient Input and Digital Health Technologies: A Regulatory Perspective Across the Product Lifecycle You Might Also Like Leveraging Natural History and RWE for Rare Approvals Mock Formal FDA Meeting: How to Respond When FDA Disagrees Platform and Basket Trials in Rare Disease: What’s Working, What Isn’t, and What It Takes to Scale Bridging the Generational Divide in Rare Disease Clinical Trials: Tailoring Communication to Maximize Recruitment, Retention, and Equity Retention by Design - Keeping Families Engaged for Multi-Year Studies
